{"id":"cetuximab-capecitabine","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Skin rash"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hand-foot syndrome"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cetuximab binds to the EGFR on the surface of cancer cells, preventing the receptor from interacting with its ligands and thereby inhibiting cell proliferation. Capecitabine is converted into 5-fluorouracil, which is then incorporated into DNA, causing DNA damage and inhibiting thymidylate synthase, a key enzyme in DNA synthesis.","oneSentence":"Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:05:24.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT05249426","phase":"PHASE1","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-04-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":48},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT05775900","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-01","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT07059949","phase":"PHASE2","title":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-30","conditions":"Unresectable Metastatic Rectal Cancer, CAPOX, Combination of Radioimmunotherapy","enrollment":80},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT03563157","phase":"PHASE1, PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":"Colorectal Cancer Metastatic, mCRC","enrollment":2},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT03387111","phase":"PHASE1, PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":"Squamous Cell Carcinoma","enrollment":4},{"nctId":"NCT06490913","phase":"PHASE2","title":"Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-11-01","conditions":"Liver Metastases of Colorectal Cancer","enrollment":33},{"nctId":"NCT05189171","phase":"","title":"MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer","status":"COMPLETED","sponsor":"Xilis, Inc.","startDate":"2022-10-25","conditions":"Colorectal Neoplasms","enrollment":46},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06322147","phase":"","title":"Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-06-01","conditions":"Colon Cancer","enrollment":50},{"nctId":"NCT05022030","phase":"PHASE2","title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-07-21","conditions":"Colo-rectal Cancer, Capecitabine, Cetuximab","enrollment":150},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT01776307","phase":"PHASE2","title":"A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-03","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT06035133","phase":"NA","title":"Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2023-11-10","conditions":"Rectal Cancer","enrollment":213},{"nctId":"NCT04262635","phase":"PHASE3","title":"Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-09-24","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT05797467","phase":"PHASE3","title":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-01","conditions":"Colorectal Cancer, Chemotherapy Effect","enrollment":366},{"nctId":"NCT05720559","phase":"PHASE2","title":"Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Cancer Hospital & Institute","startDate":"2023-03-01","conditions":"Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer","enrollment":100},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT00954876","phase":"PHASE2","title":"Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer","status":"WITHDRAWN","sponsor":"Translational Genomics Research Institute","startDate":"2009-08","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT05544812","phase":"","title":"A Small-sample, Real-world Study of Sintilimab Plus Bevacizumab/Cetuximab Plus XELOX Regimen for Conversion Therapy in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-05-01","conditions":"Colorectal Cancer","enrollment":10},{"nctId":"NCT00321100","phase":"PHASE2","title":"Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2006-04-12","conditions":"Colorectal Neoplasms","enrollment":23},{"nctId":"NCT05074966","phase":"PHASE3","title":"The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-09-06","conditions":"Colo-rectal Cancer","enrollment":314},{"nctId":"NCT00640081","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Cheryl Pugh","startDate":"2007-07","conditions":"Colorectal Cancer","enrollment":169},{"nctId":"NCT01077986","phase":"PHASE1, PHASE2","title":"Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2009-08","conditions":"Metastatic Pancreatic Cancer","enrollment":35},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT03031444","phase":"PHASE2, PHASE3","title":"Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-01","conditions":"Colorectal Cancer Stage IV, Metastasis","enrollment":135},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT01247337","phase":"PHASE2","title":"Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma","status":"COMPLETED","sponsor":"Dorte Nielsen","startDate":"2011-02-02","conditions":"Cholangiocarcinoma","enrollment":56},{"nctId":"NCT00353457","phase":"PHASE2","title":"Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma","status":"TERMINATED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2006-02","conditions":"Rectal Cancer","enrollment":6},{"nctId":"NCT00444678","phase":"PHASE2","title":"Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2004-06-01","conditions":"Colorectal Cancer, Neoplasm Metastasis","enrollment":36},{"nctId":"NCT00541112","phase":"PHASE2","title":"Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2007-10-29","conditions":"Colorectal Cancer","enrollment":19},{"nctId":"NCT04232748","phase":"","title":"Change in Body Weight During Treatment of Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Tuen Mun Hospital","startDate":"2019-01-01","conditions":"Cancer, Colorectal, Chemotherapy Effect, Weight Loss","enrollment":264},{"nctId":"NCT00398398","phase":"PHASE2","title":"Study of XELOX With Cetuximab in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2006-11","conditions":"Gastric Cancer","enrollment":44},{"nctId":"NCT04160416","phase":"PHASE2","title":"mXELOXIRI Combined With Molecular Targeted Drug in mCRC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2019-07-01","conditions":"Unresectable Metastatic Colorectal Cancer","enrollment":48},{"nctId":"NCT00183898","phase":"PHASE2","title":"Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2004-12-28","conditions":"Gastric Cancer, Esophageal Cancer","enrollment":75},{"nctId":"NCT03923036","phase":"","title":"Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2019-04","conditions":"Colorectal Cancer Metastatic","enrollment":2000},{"nctId":"NCT01310985","phase":"","title":"A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2008-03","conditions":"Colon Rectal Cancer Duke Stage Stageval","enrollment":15},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT00551213","phase":"PHASE2","title":"A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-21","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT00408564","phase":"PHASE2","title":"Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2006-01","conditions":"Pancreatic Cancer","enrollment":39},{"nctId":"NCT03567629","phase":"PHASE2","title":"Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-05-29","conditions":"mCRC","enrollment":130},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT00686166","phase":"PHASE2","title":"S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-02","conditions":"Colorectal Cancer","enrollment":83},{"nctId":"NCT00226941","phase":"PHASE1, PHASE2","title":"A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer","status":"TERMINATED","sponsor":"George Albert Fisher","startDate":"2004-06","conditions":"Rectal Cancer, Colo-rectal Cancer","enrollment":23},{"nctId":"NCT00972881","phase":"PHASE1, PHASE2","title":"Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"University College, London","startDate":"2009-04","conditions":"Rectal Cancer","enrollment":82},{"nctId":"NCT02717923","phase":"PHASE2","title":"A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2014-01","conditions":"Colorectal Neoplasms","enrollment":50},{"nctId":"NCT00483405","phase":"PHASE2","title":"Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-10","conditions":"Liver Cancer","enrollment":33},{"nctId":"NCT01718808","phase":"PHASE2","title":"Cetuximab for Elderly Patients With mCRC","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2012-11","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT01050426","phase":"PHASE2","title":"A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":17},{"nctId":"NCT02633176","phase":"PHASE3","title":"Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-01","conditions":"Nasopharyngeal Carcinoma","enrollment":120},{"nctId":"NCT01042028","phase":"PHASE1, PHASE2","title":"A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer","status":"TERMINATED","sponsor":"Per Pfeiffer","startDate":"2010-01","conditions":"Pancreatic Cancer","enrollment":39},{"nctId":"NCT01703910","phase":"PHASE2","title":"Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2012-11","conditions":"Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease","enrollment":29},{"nctId":"NCT00477711","phase":"PHASE2","title":"A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2007-03","conditions":"Gastric Cancer","enrollment":41},{"nctId":"NCT01579357","phase":"PHASE2","title":"Pharmacokinetics and Metabolic Activation of Capecitabine","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2012-02","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT00538291","phase":"PHASE2","title":"Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2005-08","conditions":"Colorectal Cancer","enrollment":13},{"nctId":"NCT00678535","phase":"PHASE3","title":"Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2008-06","conditions":"Gastric Cancer","enrollment":904},{"nctId":"NCT00305877","phase":"PHASE2","title":"Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-02","conditions":"Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer","enrollment":137},{"nctId":"NCT00795301","phase":"PHASE2","title":"A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2008-07","conditions":"Rectal Cancer","enrollment":74},{"nctId":"NCT00430027","phase":"NA","title":"Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2006-11","conditions":"Esophageal Adenocarcinoma","enrollment":8},{"nctId":"NCT00182715","phase":"PHASE3","title":"Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Velindre NHS Trust","startDate":"2005-03","conditions":"Colorectal Cancer","enrollment":2421},{"nctId":"NCT00290615","phase":"PHASE2","title":"Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Herbert Hurwitz","startDate":"2006-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT00338039","phase":"PHASE2","title":"Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Pancreatic Cancer","enrollment":69},{"nctId":"NCT00531115","phase":"PHASE2","title":"Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.","status":"TERMINATED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2007-11","conditions":"Metastatic Colorectal Cancer","enrollment":28},{"nctId":"NCT00755534","phase":"PHASE2","title":"Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC","status":"TERMINATED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-11","conditions":"Colorectal Cancer","enrollment":68},{"nctId":"NCT00482222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2007-02","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":340},{"nctId":"NCT01611506","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer","status":"TERMINATED","sponsor":"Dr Anna Dorothea Wagner","startDate":"2012-02","conditions":"Gastric Cancer","enrollment":1},{"nctId":"NCT00509561","phase":"PHASE2, PHASE3","title":"Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer","status":"UNKNOWN","sponsor":"Wales Cancer Trials Unit","startDate":"2008-02","conditions":"Esophageal Cancer","enrollment":259},{"nctId":"NCT00227734","phase":"PHASE2","title":"Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2004-06","conditions":"Colorectal Cancer","enrollment":74},{"nctId":"NCT00689702","phase":"PHASE2","title":"Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer","status":"UNKNOWN","sponsor":"Institute of Oncology Ljubljana","startDate":"2007-02","conditions":"Rectal Cancer","enrollment":43},{"nctId":"NCT00208546","phase":"PHASE3","title":"Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2005-06","conditions":"Colorectal Cancer","enrollment":750},{"nctId":"NCT00297128","phase":"PHASE2","title":"Preoperative Chemoradiation With Capecitabine and Cetuximab","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2005-10","conditions":"Rectal Cancer","enrollment":31},{"nctId":"NCT01453257","phase":"PHASE2","title":"Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Progression Free Survival","enrollment":72},{"nctId":"NCT01366118","phase":"NA","title":"Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients","status":"COMPLETED","sponsor":"Grupo Hospital de Madrid","startDate":"2009-10","conditions":"Rectal Cancer","enrollment":16},{"nctId":"NCT00254137","phase":"PHASE2","title":"Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2004-09","conditions":"Metastatic Colorectal Cancer","enrollment":92},{"nctId":"NCT00251186","phase":"PHASE2","title":"First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients","status":"TERMINATED","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2006-04","conditions":"Colorectal Cancer","enrollment":18},{"nctId":"NCT00383695","phase":"PHASE2","title":"Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer","status":"UNKNOWN","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2005-09","conditions":"Colorectal Cancer","enrollment":164},{"nctId":"NCT00964457","phase":"PHASE2","title":"Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients","status":"UNKNOWN","sponsor":"Copenhagen University Hospital at Herlev","startDate":"2009-08","conditions":"Rectum Cancer","enrollment":60},{"nctId":"NCT00506844","phase":"PHASE2","title":"Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2006-05","conditions":"Rectal Neoplasms, Neoadjuvant Treatment","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Erbitux","Xeloda"],"phase":"phase_3","status":"active","brandName":"cetuximab, capecitabine","genericName":"cetuximab, capecitabine","companyName":"Institute of Oncology Ljubljana","companyId":"institute-of-oncology-ljubljana","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while capecitabine is a prodrug that is converted into 5-fluorouracil, a thymidylate synthase inhibitor. Used for Metastatic colorectal cancer, Head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}